Open label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) with Subcutaneous IL-2 in Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML)
|Effective start/end date||10/1/16 → 7/31/21|
- Fate Therapeutics
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.